文献速递心脑血管急症重症综合管理与镇静镇痛

右束支与左束支传导阻滞对心源性休克和心脏骤停患者预后的影响

Influence of Right and Left Bundle Branch Block in Patients With Cardiogenic Shock and Cardiac Arrest.
PubMed 文献 · Crit Care Med · 2024-10-29
一句话结论在心源性休克患者中,右束支传导阻滞与30天全因死亡率独立相关(HR 1.807),而左束支传导阻滞无预后影响。

该前瞻性注册研究纳入德国一家三级学术医院ICU的248例成年心源性休克患者,比较右束支传导阻滞(RBBB)、左束支传导阻滞(LBBB)与无束支传导阻滞(BBB)对30天全因死亡率的影响。RBBB组30天全因死亡率最高(72.5%),高于LBBB组(52.9%)和无BBB组(50.0%;log-rank p=0.015);仅纳入入院时心脏骤停的CS患者时结果一致(90.0% vs. 73.3% vs. 62.2%;log-rank p=0.008)。多因素Cox回归校正乳酸、去甲肾上腺素、肌钙蛋白I、急性生理评分、SCAI休克分期和心率后,RBBB仍与30天全因死亡率独立相关(HR 1.807;95%CI 1.107-2.947;p=0.018),LBBB则无关联。RBBB与肝衰竭或严重肾衰竭发生率无关联。

要点

  • 在心源性休克患者中,RBBB组30天全因死亡率72.5%,高于LBBB组52.9%和无BBB组50.0%(log-rank p=0.015)。
  • 仅纳入入院时心脏骤停的CS患者,RBBB组30天全因死亡率90.0%,高于LBBB组73.3%和无BBB组62.2%(log-rank p=0.008)。
  • 多因素Cox回归校正乳酸、去甲肾上腺素、肌钙蛋白I、急性生理评分、SCAI休克分期和心率后,RBBB仍与30天全因死亡率独立相关(HR 1.807;95%CI 1.107-2.947;p=0.018)。
  • 同一多因素模型中,LBBB与30天全因死亡率无关联;乳酸(HR 1.065;95%CI 1.018-1.115;p=0.006)、肌钙蛋白I(HR 1.003;95%CI 1.001-1.005;p=0.001)和急性生理评分(HR 1.033;95%CI 1.001-1.066;p=0.041)与30天全因死亡率相关。
  • RBBB与肝衰竭或严重肾衰竭发生率无关联。

适用人群与场景

  • 德国一家三级学术医院ICU的成年心源性休克患者,连续纳入,最终研究队列248例。
  • 亚组分析纳入入院时发生心脏骤停的心源性休克患者。

研究设计与关键结果

  • 研究类型为前瞻性注册研究,最终研究队列248例,人群为成年心源性休克患者,无干预。
  • RBBB组30天全因死亡率72.5%,LBBB组52.9%,无BBB组50.0%(log-rank p=0.015)。
  • 仅纳入入院时心脏骤停的CS患者时,RBBB组30天全因死亡率90.0%,LBBB组73.3%,无BBB组62.2%(log-rank p=0.008)。
  • 多因素Cox回归校正乳酸、去甲肾上腺素、肌钙蛋白I、急性生理评分、SCAI休克分期和心率后,RBBB与30天全因死亡率独立相关(HR 1.807;95%CI 1.107-2.947;p=0.018),LBBB与30天全因死亡率无关联。
  • 同一多因素模型中,乳酸(HR 1.065;95%CI 1.018-1.115;p=0.006)、肌钙蛋白I(HR 1.003;95%CI 1.001-1.005;p=0.001)和急性生理评分(HR 1.033;95%CI 1.001-1.066;p=0.041)与30天全因死亡率相关。
  • RBBB与肝衰竭或严重肾衰竭发生率无关联。

证据类型、等级与局限

  • 证据类型:前瞻性注册研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,除急性生理评分、乳酸和肌钙蛋白水平外,RBBB与连续纳入的伴或不伴心脏骤停的心源性休克患者30天全因死亡率升高相关,而LBBB无预后影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The study investigates the prognostic impact of right bundle branch block (RBBB) and left bundle branch block (LBBB) in patients with cardiogenic shock (CS) compared with no bundle branch block (BBB). In patients with heart failure, existence of RBBB and LBBB has influence on prognosis.

DESIGN: Prospective registry-study.

SETTING: ICU of a tertiary academic hospital in Germany.

PATIENTS: Adult patients with CS.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Consecutive patients with CS were included. The prognostic impact of RBBB and LBBB on 30-day all-cause mortality was tested within the entire cohort and in the subgroup of CS patients with cardiac arrest at admission. The final study cohort comprised 248 patients. Patients with RBBB showed the highest 30-day all-cause mortality followed by LBBB and no BBB (72.5% vs. 52.9% vs. 50.0%; log-rank p = 0.015). These findings were consistent even after solely including CS patients with cardiac arrest (90.0% vs. 73.3% vs. 62.2%; log-rank p = 0.008). After adjustment for lactate, norepinephrine, troponin I, Acute Physiology Score, Society of Cardiovascular Angiography & Interventions shock stage, and heart rate in a multivariable Cox regression analysis, RBBB still revealed a negative impact on 30-day all-cause mortality (hazard ratio [HR], 1.807; 95% CI, 1.107-2.947; p = 0.018), whereas LBBB was not associated with 30-day all-cause mortality. In this multivariable Cox regression model lactate (HR, 1.065; 95% CI, 1.018-1.115; p = 0.006), troponin I (HR, 1.003; 95% CI, 1.001-1.005; p = 0.001), and Acute Physiology Score (HR, 1.033; 95% CI, 1.001-1.066; p = 0.041) were as well associated with 30-day all-cause mortality. Finally, no association of RBBB was found with the incidence of liver or severe renal failure.

CONCLUSIONS: Besides the Acute Physiology Score, lactate, and troponin levels, RBBB was associated with an increased 30-day all-cause mortality in consecutive CS patients with and without cardiac arrest, whereas LBBB showed no prognostic impact.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rusnak J, Schupp T, Weidner K, et al. Influence of Right and Left Bundle Branch Block in Patients With Cardiogenic Shock and Cardiac Arrest. Crit Care Med. 2024. PMID: 39470337. doi:10.1097/CCM.0000000000006459

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。